1,2,5-Benzothiadiazepine and Pyrrolo[2,1-d]-[1,2,5]Benzothiadiazepine Derivatives with Specific Anti-Human Immunodeficiency Virus Type 1 Activity
Antiviral Chemistry and Chemotherapy · 1998-04 · 9 (2) · 127-137
DOI: 10.1177/095632029800900204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antiviral Chemistry and Chemotherapy, online erschienen am 01.04.1998. Verfasst von R Di Santo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Studi Farmaceutici, Università di Roma La Sapienza, Roma, Italy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
We synthesized and tested as novel inhibitors of human immunodeficiency virus type 1 (HIV-1) bi- and tricyclic thiadiazine ring homologues of 7-chloro-2-ethyl-2 H-1,2,4-benzothiadiazin-3-(4 H)-one 1,1-dioxide, which is a compound endowed with anti-HIV-1 activity at low micromolar concentrations. Benzothiadiazepine derivatives were obtained by alkylation of 8-chloro-2,3-dihydro-3-methyl-1,2,5-benzothiadiazepin-4(5 H)-one 1,1-dioxide, which was obtained by intramolecular cyclization of 2-(2-amino-5-chloro-benzenesulphonamido) propanoic acid. Pyrrolobenzothiadiazepines were synthesized from N-substituted 5-chloro-2-(1 H-pyrrol-1-yl)benzenesulphonamides by treating with triphosgene. N 6 -substituted pyrrolo[2,1-d][1,2,5]benzothiadiazepin-7(6 H)-one 5,5-dioxides were active, thoughnot very potent. Both a chlorine atom and an unsaturated alkyl chain were found to be determinants of anti-HIV-1 activity. The highest potency was shown by a derivative with a TIBO-related 3,3-dimethylallyl chain. 2,3-Dihydro-1,2,5-benzothiadiazepin-4(5 H)-one 1,1-dioxides were scarcely active in HIV-1-infected MT-4 cell assays; however, the introduction of the dimethylallyl chain into 7-chloro-1,2,5-benzothiadiazepine moiety led to a bicyclic derivative which was more potent and less cytotoxic than the tricyclic pyrrole-containing counterpart.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dipartimento di Studi Farmaceutici, Università di Roma La Sapienza, Roma, Italy.
Zitieren
APA
Di Santo, R., Costi, R., Artico, M., Massa, S., Marongiu, M. E., Loi, A. G., De Montis, A., & La Colla, P. (1998). 1,2,5-Benzothiadiazepine and Pyrrolo[2,1-d]-[1,2,5]Benzothiadiazepine Derivatives with Specific Anti-Human Immunodeficiency Virus Type 1 Activity. Antiviral Chemistry and Chemotherapy, 9(2), 127-137. https://doi.org/10.1177/095632029800900204
Vancouver
Di Santo R, Costi R, Artico M, Massa S, Marongiu ME, Loi AG, et al. 1,2,5-Benzothiadiazepine and Pyrrolo[2,1-d]-[1,2,5]Benzothiadiazepine Derivatives with Specific Anti-Human Immunodeficiency Virus Type 1 Activity. Antiviral Chemistry and Chemotherapy. 1998;9(2):127-137. doi:10.1177/095632029800900204
BibTeX
@article{DiSanto1998,
author = {Di Santo, R and Costi, R and Artico, M and Massa, S and Marongiu, M E and Loi, A G and De Montis, A and La Colla, P},
title = {1,2,5-Benzothiadiazepine and Pyrrolo[2,1-d]-[1,2,5]Benzothiadiazepine Derivatives with Specific Anti-Human Immunodeficiency Virus Type 1 Activity},
journal = {Antiviral Chemistry and Chemotherapy},
year = {1998},
volume = {9},
number = {2},
pages = {127--137},
doi = {10.1177/095632029800900204}
}
EUVIMED